Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al Ola Abdallah, Natalie Callander, Douglas Sborov, Attaya Suvannasankha, Katja Weisel, Peter M. Voorhees, Lynsey Womersley, January Baron, Trisha Piontek, Eric Lewis, Joanna Opalinska, Ira Gupta, Adam D. Cohen

Research output: Contribution to journal › Article › peer-review

84 Scopus citations

Fingerprint

Dive into the research topics of 'Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study'. Together they form a unique fingerprint.

Medicine & Life Sciences